Exploiting the defensive sugars of HIV-1 for drug and vaccine design

被引：0

作者：

Christopher N. Scanlan

John Offer

Nicole Zitzmann

Raymond A. Dwek

机构：

[1] Glycobiology Institute,Department of Biochemistry

[2] University of Oxford,Department of Biochemistry

[3] Scripps Oxford Laboratory,undefined

[4] University of Oxford,undefined

来源：

Nature | 2007年 / 446卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

The sustained effort towards developing an antibody vaccine against HIV/AIDS has provided much of our understanding of viral immunology. It is generally accepted that one of the main barriers to antibody neutralization of HIV is the array of protective structural carbohydrates that covers the antigens on the virus's surface. Intriguingly, however, recent findings suggest that these carbohydrates, which have evolved to protect HIV and promote its transmission, are also attractive therapeutic targets.

引用

收藏

页码：1038 / 1045

页数：7

相关论文

共 50 条

[21] HIV-1 reverse transcriptase targeted for proteasomal degradation as a prototype vaccine against drug-resistant HIV-1 [J].

Starodubova, Elizaveta ;

Boberg, Andreas ;

Kashuba, Elena V. ;

Wahren, Britta ;

Karpov, Vadim ;

Isaguliants, Maria .

VACCINE, 2006, 24 (21) :4541-4547

[22] Structure-based drug design targeting an inactive RNA conformation: Exploiting the flexibility of HIV-1 TAR RNA [J].

Murchie, AIH ;

Davis, B ;

Isel, C ;

Afshar, M ;

Drysdale, MJ ;

Bower, J ;

Potter, AJ ;

Starkey, ID ;

Swarbrick, TM ;

Mirza, S ;

Prescott, CD ;

Vaglio, P ;

Aboul-ela, F ;

Karn, J .

JOURNAL OF MOLECULAR BIOLOGY, 2004, 336 (03) :625-638

[23] Defensive Driving: Directing HIV-1 Vaccine-Induced Humoral Immunity to the Mucosa with Chemokine Adjuvants [J].

Gary, Ebony N. ;

Kutzler, Michele A. .

JOURNAL OF IMMUNOLOGY RESEARCH, 2018, 2018

[24] Broadly neutralizing antibodies and vaccine design against HIV-1 infection [J].

Qian Wang ;

Linqi Zhang .

Frontiers of Medicine, 2020, 14 :30-42

[25] Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design [J].

Finney, Joel ;

Kelsoe, Garnett .

RETROVIROLOGY, 2018, 15

[26] Design of an HIV-1 vaccine that will raise neutralizing antibodies to primary isolates [J].

Montefiori, DC ;

Haynes, BF ;

Moss, B ;

Reimann, KA ;

Liao, HX ;

Zhou, JY ;

Bilska, M ;

Bolognesi, DP ;

Letvin, NL ;

Earl, PL .

11E COLLOQUE DES CENT GARDES: RETROVIRUSES OF HUMAN AIDS AND RELATED ANIMAL DISEASES, 1998, :131-136

[27] Some statistical issues in the design of HIV-1 vaccine and treatment trials [J].

Gilbert, PB .

STATISTICAL METHODS IN MEDICAL RESEARCH, 2000, 9 (03) :207-229

[28] Limitations to the structure-based design of HIV-1 vaccine immunogens [J].

Van Regenmortel, Marc H. V. .

JOURNAL OF MOLECULAR RECOGNITION, 2011, 24 (05) :741-753

[29] Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine [J].

Letourneau, Sven ;

Im, Eung-Jun ;

Mashishi, Tumelo ;

Brereton, Choechoe ;

Bridgeman, Anne ;

Yang, Hongbing ;

Dorrell, Lucy ;

Dong, Tao ;

Korber, Bette ;

McMichael, Andrew J. ;

Hanke, Tomas .

PLOS ONE, 2007, 2 (10)

[30] Broadly neutralizing antibodies and vaccine design against HIV-1 infection [J].

Wang, Qian ;

Zhang, Linqi .

FRONTIERS OF MEDICINE, 2020, 14 (01) :30-42

← 1 2 3 4 5 →